NCT02486770已完成1 期
A Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Adverse Events
研究概览
简要总结
This study will evaluate the safety profile and pharmacokinetic behavior of a single administration of Aerucin in healthy adults at three different dosages.
详细描述
This Phase I trial will be conducted as an open label trial in 15 healthy adults. All subjects will receive a specific intravenous dose of Aerucin. There are three study groups, each with a specific dose of Aerucin. Study Group 1 will receive 2.0 mg/ kg of Aerucin . Study Group 2 will receive 8.0 mg/kg of Aerucin . Study Group 3 will receive 20 mg/kg of Aerucin . The dose levels of Aerucin are selected for this study based on animal studies showing protection in an animal model and absence of adverse effects in toxicological studies. Groups will be enrolled sequentially.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Has completed the written informed consent process
- •Is male or female
- •Is age ≥18 years and ≤50 years
- •Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
- •Agrees to avoid elective surgery for the duration of the study
- •For female subjects: agrees to have avoided pregnancy from 14 days prior to Study Day 0 through the duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include: a sterile sexual partner; sexual abstinence (not engaging in any sexual intercourse); hormonal contraceptives (oral, injection, transdermal patch, or implant); vaginal ring; intrauterine device (IUD); or condom.
- •Has general good health, confirmed by medical history and physical examination
- •Has body mass index (BMI) between 18 and 30 (weight/height) -
排除标准
- •Oral temperature ≥37.5°C
- •Abnormal CBC laboratory values (per local laboratory parameters) from blood collected at screening (>5% above ULN or >5% below LLN)
- •Abnormally elevated laboratory values (per local laboratory parameters) from blood collected at screening for ALT, AST, total bilirubin, alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine (Cr), (>10% above ULN)
- •Abnormal urinalysis that, in the opinion of the investigator, is clinically significant
- •Positive screening urine test for illicit drugs (opiates, cocaine, amphetamines)
- •Has received an immunoglobulin product in the 120 days prior to Study Day 0
- •History or evidence of autoimmune disease
- •History or evidence of any past, present, or future possible immunodeficiency state, including laboratory evidence of HIV 1 infection.
- •History or evidence of chronic hepatitis
- •History of evidence of Pseudomonas infection
- •Received a systemic antibiotic with 14 days prior to Study Day 0
- •Participation in any other investigational study during the study period
- •Received immunoglobulin or blood products within 90 days prior to Study Day 0
- •Received any investigational drug therapy or investigational drug within 60 days prior to Study Day 0
- •Received immunosuppressive medications other than inhaled or topical immunosuppressants within 45 days prior to Study Day 0
- •Inability to discontinue daily medications during the study other than: oral contraceptives, vitamins, nonprescription nutritional supplements, aspirin, antihistamines inhaled corticosteroids, inhaled beta agonists, inhaled anticholinergics
- •All female subjects: currently pregnant or lactating/nursing; positive screening urine pregnancy test; or positive urine pregnancy test on the day of any study dosing
- •History or evidence of allergic disease or reaction that, in the opinion of the investigator, may compromise the safety of the subject
- •History or evidence of any other acute or chronic disease that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the drug or compromise the safety of the subject
- •Medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol
- •Any other reason at discretion of the investigator -
结局指标
主要结局
Adverse Events
时间窗: 28 and 84 days following dosing
Number and % of subjects experiencing adverse events following dosing
Serious Adverse Events
时间窗: 24 and 84 days following dosing
Number and % of subjects experiencing Serious Adverse Events following dosing
Solicited Adverse Events
时间窗: 7 days following dosing
Number and % of subjects experiencing Solicited Adverse Events following dosing
次要结局
- AUC0-∞ Area under the concentration time curve from zero to infinite time(84 days following dosing)
- TMax-Time to reach maximum plasma concentration(84 days following dosing)
- Terminal phase elimination rate(84 days following dosing)
- AUC0-last Area under the the concentration time curve(84 days following dosing)
- Terminal elimination half-life(84 days following dosing)
- CMax -Observed maximum plasma concentration(84 days following dosing)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi SyndromePrader-Willi SyndromeNCT05504395ConSynance Therapeutics10
进行中（未招募）
1 期
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVHIV InfectionsNCT06652958ViiV Healthcare102
已完成
1 期
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsHepatic InsufficiencyNCT03341884Genentech, Inc.29
已完成
1 期
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy VolunteersRespiratory Tract DisordersNCT03881163Zambon SpA24
已完成
1 期
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersNASHNCT03207425Enanta Pharmaceuticals, Inc29